Oruka Therapeutics, Inc. $ORKA Stock Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA decreased its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 35.1% during the 3rd quarter, Holdings Channel.com reports. The fund owned 401,928 shares of the company’s stock after selling 217,148 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Oruka Therapeutics were worth $33,476,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. AlphaCentric Advisors LLC raised its stake in shares of Oruka Therapeutics by 3.4% in the third quarter. AlphaCentric Advisors LLC now owns 6,752 shares of the company’s stock worth $562,000 after purchasing an additional 221 shares during the last quarter. Alps Advisors Inc. lifted its holdings in shares of Oruka Therapeutics by 43.8% in the third quarter. Alps Advisors Inc. now owns 87,745 shares of the company’s stock valued at $7,308,000 after purchasing an additional 26,731 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Oruka Therapeutics during the third quarter valued at approximately $282,000. Profund Advisors LLC boosted its position in shares of Oruka Therapeutics by 12.0% during the third quarter. Profund Advisors LLC now owns 24,649 shares of the company’s stock valued at $2,053,000 after buying an additional 2,637 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Oruka Therapeutics by 25.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,081 shares of the company’s stock worth $992,000 after buying an additional 2,482 shares in the last quarter. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Price Performance

Oruka Therapeutics stock opened at $109.50 on Wednesday. The company’s 50 day moving average price is $88.82 and its two-hundred day moving average price is $71.29. Oruka Therapeutics, Inc. has a 52 week low of $25.23 and a 52 week high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). On average, analysts forecast that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Insider Activity at Oruka Therapeutics

In other Oruka Therapeutics news, SVP Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $106.66, for a total value of $1,066,600.00. Following the sale, the senior vice president owned 15,312 shares of the company’s stock, valued at approximately $1,633,177.92. The trade was a 39.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total transaction of $734,143.86. Following the completion of the transaction, the insider owned 31,771 shares in the company, valued at approximately $2,935,004.98. The trade was a 20.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 179,950 shares of company stock worth $16,492,680. 23.49% of the stock is owned by company insiders.

Analysts Set New Price Targets

ORKA has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Guggenheim reaffirmed a “buy” rating and set a $200.00 price objective on shares of Oruka Therapeutics in a report on Monday, October 26th. BTIG Research reiterated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research note on Tuesday. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, October 13th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.00.

Oruka Therapeutics Profile

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.